BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Solace Therapeutics, Inc. Comforted by $7 Million


3/29/2012 8:58:18 AM

FRAMINGHAM, Mass. -- Medical device company Solace Therapeutics Inc. raised $7 million of a targeted $20 million in equity financing.

The company is led by Kevin G. Connors, the General Partner at Newton, Mass.-based Spray Venture Partners, which he founded in 1996. He has co-founded seven healthcare technology companies and has had interim CEO roles at nine. Prior to founding Spray, he was the founding Chief Executive Officer and Director at Vesica Medical. Earlier, he led medical device investment activity at DSV Partners in Newport Beach, Calif. He has also served on the boards of the New England Venture Capital Association and MassMEDIC.

Named in the current SEC filing along with Connors were company directors J. Daniel Cole, of Spray Venture Partners; William H. Gruber, President of Cambridge Innovation research, former CIO of Risk Management Foundation of the Harvard Medical Institutions; and William Pintauro.

Solace Therapeutics develops non-surgical office-based treatments for common bladder disorders such as stress urinary incontinence, overactive bladder, male voiding dysfunction, and lower urinary tract symptoms. Incorporated in 2002, the company is based in Framingham, Mass.



Read at BioSpace.com
Read at Mass High Tech

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES